Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruitingRare disease

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This study focuses on patients with Stage III or IV nonmucinous epithelial ovarian cancer. The research evaluates a combination treatment using two medications: niraparib (taken as oral capsules) and dostarlimab (given through intravenous infusion), along with standard platinum-based therapy. Some patients may receive placebo instead of one or both study medications to compare the effectiveness of different treatment combinations.

The purpose of this research is to determine if adding both niraparib and dostarlimab to standard platinum-based therapy improves how long patients can live without their cancer getting worse, compared to using just niraparib with platinum-based therapy. Dostarlimab is a type of medication known as an anti-PD-1 monoclonal antibody that helps the immune system fight cancer cells, while niraparib works by blocking certain proteins that help cancer cells repair themselves.

During the study, which may last up to 72 months, participants will receive either the combination of both study medications with standard therapy, or standard therapy with just one study medication, or standard therapy with placebo. The niraparib or matching placebo will be taken daily as capsules, while dostarlimab or its matching placebo will be given through an infusion into a vein. Throughout the study, participants will have regular medical check-ups to monitor their health and how well the treatment is working.

The research process

The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial treatment phase

    You will receive a combination of platinum-based therapy with other medications. The treatment will be given through oral capsules and intravenous infusion.

    The study medications include niraparib (taken as capsules) and dostarlimab (given as an infusion), or their placebos, depending on your assigned treatment group.

    Your blood pressure should be stable (not higher than 140/90 mmHg) during the treatment.

  2. Step 2

    Regular health assessments

    Your health status will be monitored through regular blood tests. The following values will be checked:

    - Blood cell counts (without receiving blood transfusions for 2 weeks before testing)

    - Kidney function through creatinine tests

    - Liver function through various blood tests

    You will need to complete quality of life questionnaires throughout the study period.

  3. Step 3

    Disease monitoring

    Your condition will be regularly assessed to check if the cancer has progressed.

    Imaging tests will be performed to measure how the tumors are responding to treatment.

    The study will track how long it takes before you might need any additional cancer treatments.

  4. Step 4

    Long-term follow-up

    The study will continue monitoring your health status until 2026.

    Your overall survival and quality of life will be tracked throughout the study period.

    If you need to start other cancer treatments, this information will be recorded as part of the study data.

Who can join the trial?

16 criteria

  • Must be a female aged 18 years or older
  • Must be diagnosed with Stage 3 or 4 non-mucinous epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
  • Must have adequate physical performance status (ECOG score of 0 or 1, meaning able to perform daily activities with minimal limitations)
  • Must have normal or controlled blood pressure (systolic not higher than 140 mmHg and diastolic not higher than 90 mmHg)
  • Must be able to take oral medications
  • Must provide blood samples for testing
  • Must provide tumor tissue samples for laboratory analysis
  • Must have adequate organ function, including:
    • Sufficient blood cell counts
    • Normal kidney function
    • Normal liver function
    • If able to become pregnant, must:
      • Have a negative pregnancy test before starting treatment
      • Be post-menopausal (no periods for over 1 year)
      • Be surgically sterilized, or
      • Use effective contraception during the study and for 180 days after the last treatment
      • Must be willing to complete quality of life questionnaires throughout the study
      • Must be able to understand and agree to the study procedures by providing written informed consent

Who cannot join the trial?

14 criteria

  • Age below 18 years
  • Male patients (study is for females only)
  • Previous treatment with dostarlimab or niraparib (medications used in the study)
  • Known allergy or hypersensitivity to the study medications
  • Presence of mucinous ovarian cancer (a specific type of ovarian tumor)
  • Ovarian cancer stages other than stage 3 or 4
  • Presence of other active cancers requiring treatment
  • Severe heart conditions or uncontrolled high blood pressure
  • Significant liver or kidney problems
  • Pregnancy or breastfeeding
  • Participation in other clinical trials within the past 30 days
  • Mental conditions that could interfere with following study procedures
  • Active, uncontrolled infections
  • History of other medical conditions that could interfere with the study medications
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

Dostarlimab (also known as TSR-042) is a medication that helps your immune system fight cancer cells. It belongs to a group of drugs called immunotherapy. It works by blocking a protein that cancer cells use to hide from your immune system, allowing your body's natural defenses to better recognize and attack the cancer. Niraparib is a medication used to treat ovarian cancer. It belongs to a class of drugs called PARP inhibitors, which work by preventing cancer cells from repairing their damaged DNA, which can help stop them from growing and spreading. Platinum-based therapy is a standard chemotherapy treatment that includes medications containing platinum. These medications work by damaging the DNA of cancer cells, which prevents them from dividing and causes them to die. This is a common first-line treatment for ovarian cancer.

What is already known about the treatment

  • Dostarlimab

    An immunotherapy medication administered through intravenous infusion, which belongs to the class of PD-1 inhibitors. This drug works by helping the immune system recognize and attack cancer cells by blocking the PD-1 pathway that cancer cells use to hide from immune cells. It is primarily used in the treatment of advanced ovarian cancer, particularly in combination with standard platinum-based chemotherapy. The drug is currently being studied in clinical trials as a first-line treatment for Stage III or IV non-mucinous epithelial ovarian cancer.

  • Niraparib

    An oral medication belonging to the class of PARP inhibitors, taken as a capsule once daily. This drug works by blocking DNA repair in cancer cells, making them more susceptible to death, particularly in patients with specific genetic mutations. It is used in the treatment of advanced ovarian cancer, typically in combination with other cancer treatments, and is being investigated as part of first-line therapy for Stage III or IV non-mucinous epithelial ovarian cancer in combination with platinum-based chemotherapy.

Investigated diseases

Non-mucinous Epithelial Ovarian Cancer - A type of ovarian cancer that develops from the epithelial cells covering the surface of the ovary, specifically characterized by the absence of mucin-producing cells. This cancer begins in the tissue that covers the ovaries, forming solid tumors that can spread to nearby tissues. The disease typically develops in stages, with stages 3 and 4 indicating that cancer has spread beyond the ovaries. It can progress to involve nearby pelvic organs, lymph nodes, and in advanced cases, distant organs. The cancer cells in this type have distinct microscopic features that differentiate them from mucinous types of ovarian cancer.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-510605-28-00Protocol code213350/3000-03-005Estimated enrolment1 655 patientsSponsorTesaro Inc.

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.